| Filed On | Filing |
|---|---|
| 06 Dec 2022 |
8-K/A: Results of Operations and Financial Condition
INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual meeting. |
Loading...
